Search
News Archive
Categories
Growing revenues for marine ingredient company Aqua Bio Technology
Posted On: June 7, 2013Aqua Bio Technology ASA (Oslo Axess: ABT) recently announced its first quarter 2013 financial results. The Company continued its revenue build-up and posted an EBITDA of 3.9 million.
ABT’s revenues were NOK 7.2 million in the first quarter, against NOK 3.4 million in the previous quarter. In the first quarter of 2012 the Company had revenues of NOK 11.9 million, which included sign-on fees for major contracts.
The sales growth is reflected in the NOK 3.9 million EBITDA, which is up from an EBITDA of NOK 0.2 million the previous quarter. The first quarter of 2012 provided EBITDA of NOK 9.6 million.
Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT’s ingredients Aquabeautine XL, Dermaclarine and Beauty Propelline are marine solutions derived from the hatching fluid of salmon, while Oceanx Oil in Serum is based on extract from seaweed.
Release of Mar. Drugs, Volume 11, Issue 5 (May 2013), Pages 1427-1762
Posted On: June 7, 2013MDPI announces the publication of the following issue:
Mar. Drugs, Volume 11, Issue 5 (May 2013), Pages 1427-1762
http://www.mdpi.com/1660-3397/
Nofima Scientists Develop Biodegradable Food Packaging Made of Chitin & Chitosan from Shrimp Shell
Posted On: May 22, 2013Scientists at Nofima are participating in a major EU-financed project in which “active” packaging based on raw materials from shrimp shell improves and conserves food products – and after use the packaging biodegrades. Environmentally stubborn plastic is getting competition from biodegradable packaging made of chitin and chitosan from shrimp shell.
Nofima’s part of the project equates to around NOK 1 million over a two-year period. Together with the coordinator, Italian company Mavi, the majority of the project involves four medium-sized companies in EU and three research centres.
“Our job is to ensure food contact safety in the project and quantify the effect on bacteria. Chitosan used as an integrated part of the packaging can have an antibacterial effect on the food products,” says Morten Sivertsvik, Director of Research at Nofima’s department for Processing Technology in Stavanger.
“The EU has strict regulations in this area, and our role is to see that the active packaging have a positive and not negative impact on the food products. The chitosan-based fibres that are used in the packaging are based on nanotechnology, so we are talking about minute particles that by no means have to break down so they come in the food products.”
Sivertsvik has worked on packaging technology at Nofima, Europe’s largest food research institute, since 1992.
Supreme Biotechnologies launches new joint care product based on Astaxanthin and Omega-3
Posted On: May 22, 2013Supreme Biotechnologies, producers of AstaSupreme Astaxanthin, have launched a unique formula which combines Astaxanthin, Curcumin and Omega 3.
Supreme Biotechnologies CEO Tony Dowd says the new product is designed specifically to target inflammation in sore joints and tendons, by combining three ingredients that have been clinically validated as natural anti-inflammatory agents.
“Many people suffering from painful inflamed joints often take Astaxanthin, Curcumin and Omega 3 separately,” Dowd says. “So, we worked with a natural health consultant to combine the right quantities of each of these three ingredients, to create a powerhouse formula for painful joints.
Biotec Pharmacon subsidiary awarded NOK 5 million research grant
Posted On: February 24, 2013ArcticZymes AS, a subsidiary company of Biotec Pharmacon ASA, has received a grant of NOK 5 million from the The Research Council of Norway, for a project titled “Functionalization of enzymes from marine bioprospecting”. The total project budget is NOK approx. 10 million over 3 years.
The project is a user driven innovation project which aims to accelerate the commercialization of new functionalized enzyme solutions in the Bioprospecting program under The Research Council’s Biotek2021 initiative.
ArcticZymes’ enzyme portfolio is expanding quickly, primarily due to the progress of strategic partnerships with MabCent, MARZymes and others, and results from the ongoing InnoZymes project which received funding from The Research Council’s Functional Genomics in Norway (FUGE) program in April 2011
Marine enzyme can decongest sinusitis
Posted On: February 24, 2013A new nasal spray from a marine microbe will help clear chronic sinusitis, which causes nasal congestion, difficulty in breathing, pain and swelling around your eyes and cheeks. A team of scientists and surgeons from Newcastle University are developing the spray with an enzyme isolated from a marine bug Bacillus licheniformis, found on the surface of seaweed.
Lab experiments showed that the enzyme, called NucB, dispersed 58 per cent of biofilms in chronic sinusitis formed by the marine bug. The biofilm acts as a slimy barrier to protect bugs from sprays or antibiotics, the journal Public Library of Science ONE reports.
FIRST NOTICE AND CALL FOR SYMPOSIA IMBC 2013
Posted On: December 4, 201210th International Marine Biotechnology Conference
Genome to phenome: understanding to sustainable use
Brisbane Convention and Exhibition Centre from 11-15 November 2013.
The International Marine Biotechnology Conference is the premier meeting in marine biotechnology and micro-biotechnologies. Dating back to 1989, previous IMBCs have been held in Japan (twice), The United States of America, Norway, Italy, Australia, Canada, Israel, China and Australia.
The 10th IMBC will showcase leading-edge developments in marine biotechnologies, from algal biotechnologies through to whole-organism biotechnologies and the application of marine genomics, metagenomics and chemistry in biomedicine, bioprocessing and aquaculture. Sustainable policies and practices will be at the fore throughout the conference.
Over the coming months further details about this meeting will come available, including a list of international plenary speakers and details on specific symposia. Along with this information, will be details on the registration, abstract submissions and trade displays.
Marine bioprospecting – a role for bioresource centers in the 21st century
Posted On: November 19, 2012Marine bioprospecting – a role for bioresource centers in the 21st century. A presentation by Dr Willie Wilson (Director of National Center for Marine Algae and Microbiota, Bigelow Laboratory for Ocean Sciences, USA) presentation at the Oceans of Potential conference, Tuesday 11th September, Plymouth, UK
Marine biotechnology advances towards applications in new functional foods
Posted On: November 19, 2012The marine ecosystem is still an untapped reservoir of biologically active compounds, which have considerable potential to supply food ingredients towards development of new functional foods. With the goal of increasing the availability and chemical diversity of functional marine ingredients, much research has been developed using biotechnological tools to discover and produce new compounds.
This review summarizes the advances in biotechnological tools for production of functional ingredients, including enzymes, for the food industry. Tools involving biotechnological processes (bioreactors, fermentations, bioprocessing) and those involving genetic research designated as molecular biotechnology are discussed highlighting how they can be used in the controlled manipulation and utilization of marine organisms as sources of food ingredients, as well as discussing the most relevant shortcomings towards applications in new functional foods.
Cyanotech Reports Financial Results
Posted On: November 17, 2012Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, including BioAstin® Natural Astaxanthin and Hawaiian Spirulina Pacifica®, has announced financial results for the second quarter and first six months of fiscal year 2013, ended September 30, 2012.
Second Quarter 2013
For the second quarter of fiscal 2013 compared to the second quarter of fiscal 2012, revenues were $6,936,000 compared to $5,989,000, an increase of 16%. Gross profit was $2,812,000, with gross profit margin of 40.5%, compared to gross profit of $2,790,000 and gross profit margin of 46.6%. Net income was $476,000 or $0.08 per diluted share, compared to net income of $875,000 or $0.16 per diluted share.
Host
 |
Partners
  |
Sponsors
 |
Share Aquapreneur
